Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20267 Citations
AOD-960416 residuesYLRIVQCRSVEGSCGFEach bubble = one amino acid. Size = residue mass. Color = chemical class.AOD-9604 targets fat cells through the beta-3 adrenergic receptor, a mechanism separate from appetite-based weight loss drugs. Phase IIa data showed 2.8 kg fat loss at 12 weeks. The Phase IIb trial failed its primary endpoint. Community users treat it as a mild recomposition stacking add-on, not a standalone solution.
200mcg · Daily
Summary: Add 2mL BAC water to your 5mg vial. Draw to 8.0 units on a U-100 syringe for a 200mcg dose. This vial will last 25 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 200mcg | Daily |
| Moderate | 300mcg | Daily |
| Aggressive | 500mcg | Daily |
Start at 200 to 250 mcg for the first two weeks. There's no rush to the full dose, and you'll want to confirm tolerability before committing to a 12-week run. Reconstitution math for a 5 mg vial: add 2 mL bacteriostatic water. That gives you 2,500 mcg/mL, or 25 mcg per unit on a 100-unit insulin syringe. For a 250 mcg dose, draw 10 units. For 300 mcg, draw 12 units. For 500 mcg, draw 20 units. Fasted dosing is non-negotiable. The lipolytic mechanism runs through beta-3 adrenergic receptor signaling, which insulin suppresses. No food, no cream in coffee, no BCAAs for at least two hours before injection. Wait 30 to 60 minutes after injection before eating. The thing most beginners miss: AOD-9604 is not a GLP-1. There's no appetite suppression. You won't feel different. Track progress with waist circumference or DEXA, not the bathroom scale; scale weight poorly reflects what this peptide actually does. A 5 mg vial at 400 mcg daily lasts 12.5 days. A full 12-week course burns through roughly 7 vials ($315 to $525 at current research-chemical pricing).
Dosing based on Phase 2 trial: AOD-9604 in obese adults (Metabolic 2001) — 12 published references.View all sources →
Cross-check your AOD-9604 reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
AOD-9604 targets fat cells through the beta-3 adrenergic receptor, a mechanism separate from appetite-based weight loss drugs. Phase IIa data showed 2.8 kg fat loss at 12 weeks. The Phase IIb trial failed its primary endpoint. Community users treat it as a mild recomposition stacking add-on, not a standalone solution.
